Affordable cancer care

The Lancet Oncology

Volumn 13, Issue 1, 2012, Pages e2-

  Brábek, Jan ^a   Fernandes, Michael ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Medbase   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CARE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RESEARCH; CLINICAL EVALUATION; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; FUNDING; HEALTH CARE; HUMAN; LETTER; MEDICAL SOCIETY; METASTASIS; PRIORITY JOURNAL; PROFIT; SOLID TUMOR; TUMOR VOLUME;

EID: 84855321136     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70419-3     Document Type: Letter

References (8)

1. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:933-980.
2. Elvin P, Garner AP Tumor invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol 2005, 5:374-381.
3. Fernandes M Letter. Judging a cancer drug-Avastin's story. New York Times May 25, 2011.
4. Gallagher J Cancer cost 'crisis' warning from oncologists. BBC News, Sep 26, 2011 (accessed Nov 11, 2011). http://www.bbc.co.uk/news/health-15032862.
5. Eccles SA, Welch DR Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369:1742-1757.
6. Sleeman J, Steeg PS Cancer metastasis as a therapeutic target. Eur J Cancer 2010, 46:177-180.
7. Barker R A flexible blueprint for the future of drug development. Lancet 2010, 375:357-359.
8. Cooksey D A review of UK health research funding (accessed Nov 11, 2011). http://www.hm-treasury.gov.uk/d/pbr06_cooksey_final_report_636.pdf.